Toi M, Imoto S, Ishida T, Ito Y, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22:74-84.
PMID: 33387497